Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid... Oncol Ther (2019) 7:131–139 https://doi.org/10.1007/s40487-019-00099-9 ORIGINAL RESEARCH Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients . . . . Marta Sese ´ Rosa Somoza Inmaculada Maestu Maria Martı ´n Ureste . . . Alfredo Sanchez Juan Felipe Cordoba Irene Sansano . . ´ ´ Griselda Venturas Santiago Ramon y Cajal Javier Hernandez-Losa Received: May 31, 2019 / Published online: August 19, 2019 The Author(s) 2019 development of new techniques for studying ABSTRACT tumor biomarkers in liquid biopsies, such as mutation analysis in cell-free DNA (cfDNA). Introduction: Precision medicine has revolu- cfDNA analysis can accurately determine tumor tionized the understanding and treatment of progression and prognosis and more effectively cancer by identifying subsets of patients who identify appropriate targeted therapies. How- are amenable to specific treatments according ever, cfDNA is vulnerable, particularly during to their molecular characteristics, as exempli- plasma sample shipping. fied by epidermal growth factor receptor (EGFR) Objective: We compared the cell- and DNA- mutations in non-small cell lung cancer stabilizing properties of cell-free DNA blood (NSCLC). Although tissue biopsy is the gold collection tubes (BCTs) with those of the tradi- standard for determining molecular alterations tional shipping http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients

Loading next page...
 
/lp/springer-journals/validation-of-cell-free-dna-collection-tubes-for-determination-of-egfr-k64ExK4jGK
Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-00099-9
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2019) 7:131–139 https://doi.org/10.1007/s40487-019-00099-9 ORIGINAL RESEARCH Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients . . . . Marta Sese ´ Rosa Somoza Inmaculada Maestu Maria Martı ´n Ureste . . . Alfredo Sanchez Juan Felipe Cordoba Irene Sansano . . ´ ´ Griselda Venturas Santiago Ramon y Cajal Javier Hernandez-Losa Received: May 31, 2019 / Published online: August 19, 2019 The Author(s) 2019 development of new techniques for studying ABSTRACT tumor biomarkers in liquid biopsies, such as mutation analysis in cell-free DNA (cfDNA). Introduction: Precision medicine has revolu- cfDNA analysis can accurately determine tumor tionized the understanding and treatment of progression and prognosis and more effectively cancer by identifying subsets of patients who identify appropriate targeted therapies. How- are amenable to specific treatments according ever, cfDNA is vulnerable, particularly during to their molecular characteristics, as exempli- plasma sample shipping. fied by epidermal growth factor receptor (EGFR) Objective: We compared the cell- and DNA- mutations in non-small cell lung cancer stabilizing properties of cell-free DNA blood (NSCLC). Although tissue biopsy is the gold collection tubes (BCTs) with those of the tradi- standard for determining molecular alterations tional shipping

Journal

Oncology and TherapySpringer Journals

Published: Aug 19, 2019

References